These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38010641)

  • 81. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
    Marotte L; Capitao M; Deleine C; Beauvais T; Cadiou G; Perrin J; Chérel M; Scotet E; Guilloux Y; Bruchertseifer F; Morgenstern A; Jarry A; Gaschet J; Labarriere N
    Oncoimmunology; 2021; 10(1):1940676. PubMed ID: 34239774
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
    Barclay J; Creswell J; León J
    Arch Esp Urol; 2018 May; 71(4):393-399. PubMed ID: 29745928
    [TBL] [Abstract][Full Text] [Related]  

  • 84. PD-L1 and PD-L2 immune checkpoint protein induction by type III interferon in non-small cell lung cancer cells.
    Larsen TV; Daugaard TF; Gad HH; Hartmann R; Nielsen AL
    Immunobiology; 2023 May; 228(3):152389. PubMed ID: 37146414
    [TBL] [Abstract][Full Text] [Related]  

  • 85. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 86. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
    Lee Y; Shin JH; Longmire M; Wang H; Kohrt HE; Chang HY; Sunwoo JB
    Clin Cancer Res; 2016 Jul; 22(14):3571-81. PubMed ID: 26864211
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
    Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
    Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
    [TBL] [Abstract][Full Text] [Related]  

  • 88. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
    Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
    Liu M; Sun Q; Wei F; Ren X
    Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
    Song N; Bai M; Che X; Li Z; Jing W; Li C; Teng Z; Qu X; Liu Y
    Med Oncol; 2020 Apr; 37(5):47. PubMed ID: 32277292
    [TBL] [Abstract][Full Text] [Related]  

  • 93. CD44/PD-L1-mediated networks in drug resistance and immune evasion of breast cancer stem cells: Promising targets of natural compounds.
    Malla R; Jyosthsna K; Rani G; Purnachandra Nagaraju G
    Int Immunopharmacol; 2024 Sep; 138():112613. PubMed ID: 38959542
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification ACTA2 and KDR as key proteins for prognosis of PD-1/PD-L1 blockade therapy in melanoma.
    Wang Y; Li Z; Zhang Z; Chen X
    Animal Model Exp Med; 2021 Jun; 4(2):138-150. PubMed ID: 34179721
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Significant Association of PD-L1 With CD44 Expression and Patient Survival: Avenues for Immunotherapy and Cancer Stem Cells Downregulation in Pancreatic Cancers.
    Ali SM; Adnan Y; Ahmad Z; Chawla T; Ali SMA
    J Cancer Epidemiol; 2024; 2024():3448648. PubMed ID: 39148690
    [No Abstract]   [Full Text] [Related]  

  • 96. PD-L1 - targeted magnetic fluorescent hybrid nanoparticles: Illuminating the path of image-guided cancer immunotherapy.
    Li X; Younis MH; Wei W; Cai W
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2240-2243. PubMed ID: 36943430
    [No Abstract]   [Full Text] [Related]  

  • 97. [Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].
    Sotnikova TN; Polushkina TV; Danilova NV
    Arkh Patol; 2023; 85(6):70-75. PubMed ID: 38010641
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
    Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
    Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives.
    Cazzato G; Lettini T; Colagrande A; Trilli I; Ambrogio F; Laface C; Parente P; Maiorano E; Ingravallo G
    Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372432
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial Relationship.
    Fiorentino V; Pizzimenti C; Franchina M; Pepe L; Russotto F; Tralongo P; Micali MG; Militi GB; Lentini M
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.